Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 25;37(1).
doi: 10.1002/gps.5625. Online ahead of print.

Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data

Andrew Sommerlad  1   2 , Nomi Werbeloff  1   2   3 , Gayan Perera  4   5 , Tanya Smith  6 , Harry Costello  7 , Christoph Mueller  4   5 , Andrey Kormilitzin  8 , Matthew Broadbent  5 , Alejo Nevado-Holgado  8   9 , Simon Lovestone  9   10 , Robert Stewart  4   5 , Gill Livingston  1   2
Affiliations

Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data

Andrew Sommerlad et al. Int J Geriatr Psychiatry. .

Abstract

Objectives: Evidence in mouse models has found that the antidepressant trazodone may be protective against neurodegeneration. We therefore aimed to compare cognitive decline of people with dementia taking trazodone with those taking other antidepressants.

Methods: Three identical naturalistic cohort studies using UK clinical registers. We included all people with dementia assessed during 2008-16 who were recorded taking trazodone, citalopram or mirtazapine for at least 6 weeks. Linear mixed models examined age, time and sex-adjusted Mini-mental state examination (MMSE) change in people with all-cause dementia taking trazodone compared with those taking citalopram and mirtazapine. In secondary analyses, we examined those with non-vascular dementia; mild dementia; and adjusted results for neuropsychiatric symptoms. We combined results from the three study sites using random-effects meta-analysis.

Results: We included 2,199 people with dementia, including 406 taking trazodone, with mean 2.2 years follow-up. There was no difference in adjusted cognitive decline in people with all-cause or non-vascular dementia taking trazodone, citalopram or mirtazapine in any of the three study sites. When data from the three sites were combined in meta-analysis, we found greater mean MMSE decline in people with all-cause dementia taking trazodone compared to those taking citalopram (0·26 points per successive MMSE measurement, 95% CI 0·03-0·49; p = 0·03). Results in sensitivity analyses were consistent with primary analyses.

Conclusions: There was no evidence of cognitive benefit from trazodone compared to other antidepressants in people with dementia in three naturalistic cohort studies. Despite preclinical evidence, trazodone should not be advocated for cognition in dementia.

Keywords: cognitive function; cohort study; dementia; pharmacoepidemiology; repurposing; trazodone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Gauthier S, Albert M, Fox N, et al. Why has therapy development for dementia failed in the last two decades? Alzheimer's Dement: J Alzheimer's Assoc. 2016;12(1):60-64.
    1. Halliday M, Radford H, Zents KA, et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain. 2017;140(6):1768-1783.
    1. Halliday M, Mallucci GR. Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. Neuropathology Appl Neurobiol. 2015;41(4):414-427.
    1. Smith HL, Mallucci GR. The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain. 2016;139(8):2113-2121.
    1. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res. 2011;1415:136-148.

LinkOut - more resources